

PART I					(Rs.in lakhs)
Statement of Standalone Un Audited Results for the quarter ended 30 June, 2014					
SI No.	Particulars	Quarter ended			Previous year ended 31 March, 2014
		30.06.2014	31.03.2014	30.06.2013	
		Un Audited	Audited	Un Audited	Audited
1	Income from Operations				
	(a) Net sales / Income from Operations (Net of Excise duty)	25,344.90	29,184.44	20,871.18	1,00,167.99
	(b) Other operating income	-	-	-	-
	Total Income from operations (net)	25,344.90	29,184.44	20,871.18	1,00,167.99
2	Expenses				
	(a) Cost of material Consumed	14,490.67	15,348.27	14,036.04	58,735.64
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in Inventories of Finished goods, Work in progress and Stock-in-trade	(85.14)	1,826.33	(1,228.85)	(237.62)
	(d) Employee Benefits Expense	1,830.12	1,833.90	1,643.97	6,927.38
	(e) Depreciation	965.74	932.12	501.19	2,639.79
	(f) Manufacturing Expenses	1,382.10	1,370.15	1,207.49	5,518.25
	(g) Freight outward & clearing charges	1,207.63	1,608.48	1,084.72	5,184.14
	(h) R & D Expenses	46.92	274.64	97.35	567.64
	(i) Other expenditure	1,568.11	1,528.86	1,144.00	7,171.74
	Total	21,406.15	24,722.76	18,485.91	86,506.96
3	Profit from Operations before Other Income, finance costs & Exceptional Items (1- 2)	3,938.76	4,461.68	2,385.27	13,661.03
4	Other Income	31.38	121.98	170.07	364.75
5	Profit from Ordinary activities before finance costs and exceptional items (3 - 4)	3,970.14	4,583.66	2,555.34	14,025.78
6	Finance Costs	655.10	706.91	340.97	1,892.70
7	Profit from Ordinary activities after finance costs but before exceptional items (5 - 6)	3,315.03	3,876.75	2,214.37	12,133.08
8	Exceptional items	-	-	-	-
9	Profit from Ordinary activities before Tax (7 - 8)	3,315.03	3,876.75	2,214.37	12,133.08
10	Tax expense	1,080.09	1,272.50	741.17	4,031.94
11	Net Profit from ordinary activities after tax (9 - 10)	2,234.94	2,604.26	1,473.20	8,101.14
12	Extraordinary items (net of tax expense)	-	-	-	-
13	Net Profit for the period (11 - 12)	2,234.94	2,604.26	1,473.20	8,101.14
14	Paid-up share capital (Face Value of Rs.10/- each)	2,035.62	2,028.12	2,014.72	2,028.12
15	Reserves excluding Revaluation Reserve	34,683.10	32,403.15	26,526.90	32,403.15
16	Earnings per Share				
	(a) Basic Earnings per share (Rs.)	11.01	12.88	7.32	40.06
	(b) Diluted Earning per share (Rs)	10.77	12.63	7.13	39.30

PART II

Select Information for the Quarter and year ended 30 June, 2014					
SI No.	Particulars	Quarter ended			Previous year ended 31 March, 2014
		30.06.2014	31.03.2014	30.06.2013	
A					
1	Public Shareholding				
	- No. of shares	1,04,34,688	1,03,70,988	1,11,99,097	1,03,70,988
	- Percentage of shareholding	51.26%	51.14%	55.59%	51.14%
2	Promoters and promoter group				
	Shareholding				
	(a) Pledged/Encumbered				
	Number of shares	15,04,330	24,45,830	19,51,000	24,45,830
	Percentage of shares to promoter group	15.16%	24.68%	21.80%	24.68%
	Percentage of shares to total capital	7.39%	12.06%	9.68%	12.06%
	(b) Non-encumbered				
	Number of shares	84,17,136	74,64,336	69,97,057	74,64,336
	Percentage of shares to promoter group	84.84%	75.32%	78.20%	75.32%
	Percentage of shares to total capital	41.35%	36.80%	34.73%	36.80%

SI No.	Particulars	Quarter ended 30.06.2014
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the Quarter	NIL
	Received during the quarter	19
	Disposed of during the quarter	19
	Remaining unresolved at the end of the quarter	NIL

- The financial results for the quarter ended 30th June, 2014 have been reviewed by the Audit Committee on 23rd July, 2014 and approved by the Board of Directors at its meeting held on 24th July, 2014.
- The auditors of the company carried out limited review of the above financial results.
- Pursuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by the Ministry of Company Affairs, the company has opted to capitalise foreign currency gains and losses on loans utilised for purchase of fixed assets.
- During the quarter Gain of Rs.108.01 lakhs (Loss of Rs.1,478.51 Lakhs for the Quarter ended 30 June 2013) was transferred to fixed assets.
- Auctus Pharma Limited, a wholly owned subsidiary company has filed a petition with the Hon'ble High Court of Judicature at Hyderabad for the states Andhra Pradesh and Telangana for amalgamation with Granules India Limited with effect from 1st April 2013, the Appointed Date. Subsequent to approval of Hon'ble High Court of Judicature at Hyderabad for the States of Andhra Pradesh and Telangana, the accounts of Granules India Limited will be revised accordingly.
- As per clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for persual on the Company's website as well as on the stock exchanges' websites as stated below:
www.granulesindia.com, www.bseindia.com and www.nse-india.com
- The Company operates only in the segment of Pharmaceuticals.
- Figures are regrouped wherever necessary.
- The Company, during the quarter has allotted 75,000 equity shares of Rs.10/- each, fully paid up, on exercise of options by employees, in accordance with the Company's Employee Stock Option Scheme(s).

for and on behalf of the Board

Chairman



Place : Hyderabad
Date : 24th July, 2014



(Rs in Lakhs)

PART I					
Statement of Consolidated Un-Audited Results for the Quarter ended 30th June, 2014					
SI No.	Particulars	Quarter ended			Previous year ended 31 March, 2014
		30.06.2014	31.03.2014	30.06.2013	
		Un-Audited	Audited	Un-Audited	Audited
1	Income from Operations				
	(a) Net sales / Income from Operations (Net of Excise duty)	31,102.08	31,747.31	22,829.36	1,09,586.48
	(b) Other operating income	-	-	-	-
	Total Income from operations (net)	31,102.08	31,747.31	22,829.36	1,09,586.48
2	Expenses				
	(a) Cost of material Consumed	17,358.57	18,377.21	14,845.20	67,131.23
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in Inventories of Finished goods, Work in progress and Stock-in-trade	712.77	843.81	(1,174.74)	(2,606.11)
	(d) Employee Benefits Expense	2,595.60	2,354.32	2,109.02	8,788.56
	e) Depreciation	1,167.17	1,056.37	568.06	2,981.25
	f) Manufacturing Expenses	1,975.12	1,759.68	1,491.03	6,702.12
	g) Freight outward & clearing charges	1,271.32	1,628.66	1,101.62	5,274.38
	h) R & D Expenses	75.32	300.88	118.64	679.22
	i) Other expenditure	1,832.67	1,474.86	1,366.60	7,788.03
	Total	26,988.54	27,795.80	20,425.43	96,738.68
	Profit from Operations before Other Income, finance costs & Exceptional Items (1- 2)	4,113.54	3,951.50	2,403.93	12,847.79
3	Other Income	41.98	148.87	184.88	431.09
	Profit from Ordinary activities before finance costs and exceptional items (3 - 4)	4,155.52	4,100.37	2,588.81	13,278.89
6	Finance Costs	742.63	778.90	368.83	2,042.73
7	Profit from Ordinary activities after finance costs but before exceptional items (5 - 6)	3,412.89	3,321.47	2,219.98	11,236.16
8	Exceptional items	-	-	-	-
9	Profit from Ordinary activities before Tax (7 - 8)	3,412.89	3,321.47	2,219.98	11,236.16
10	Tax expense	1,126.23	958.97	750.72	3,713.03
11	Net Profit from ordinary activities after tax (9 - 10)	2,286.65	2,362.50	1,469.26	7,523.13
12	Extraordinary items (net of tax expense)	-	-	-	-
13	Net Profit for the period (11 - 12)	2,286.65	2,362.50	1,469.26	7,523.13
14	Paid-up share capital (Face Value of Rs.10/- each)	2,035.62	2,028.12	2,014.72	2,028.12
15	Reserves excluding Revaluation Reserve	35,869.45	33,542.61	26,918.46	33,542.61
16	Earnings per Share				
	(a) Basic Earnings per share (Rs.)	11.27	11.68	7.30	37.20
	(b) Diluted Earning per share (Rs)	11.02	11.46	7.11	36.49

PART II

Select Information for the Quarter ended 30 June, 2014					
SI No.	Particulars	Quarter ended			Previous year ended 31 March, 2014
		30.06.2014	31.03.2014	30.06.2013	
A					
1	Public Shareholding				
	- No. of shares	1,04,34,688	1,03,70,988	1,11,99,097	1,03,70,988
	- Percentage of shareholding	51.26%	51.14%	55.59%	51.14%
2	Promoters and promoter group				
	Shareholding				
	a) Pledged/Encumbered				
	Number of shares	15,04,330	24,45,830	19,51,000	24,45,830
	Percentage of shares to promoter group	15.16%	24.68%	21.80%	24.68%
	Percentage of shares to total capital	7.39%	12.06%	9.68%	12.06%
	b) Non-encumbered				
	Number of shares	84,17,136	74,64,336	69,97,057	74,64,336
	Percentage of shares to promoter group	84.84%	75.32%	78.20%	75.32%
	Percentage of shares to total capital	41.35%	36.80%	34.73%	36.80%
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the Quarter	Nil			
	Received during the quarter	19			
	Disposed of during the quarter	19			
	Remaining unresolved at the end of the quarter	Nil			

- The financial results for the quarter and year ended 30th June, 2014 have been reviewed by the Audit Committee on 23rd July, 2014 and approved by the Board of Directors at its meeting held on 24th July, 2014.
- The auditors of the company carried out limited review of the above financial results.
- The subsidiaries considered for the consolidated financial statement as on 30th June, 2014 are Granules USA Inc., GIL Life Sciences Pvt Ltd, Auctus Pharma Limited (Wholly owned subsidiary companies) and Granules Biocause Pharmaceutical Co., Ltd., Granules Omnicem Pvt Ltd (50% Joint Venture Companies).
- Auctus Pharma Limited, a wholly owned subsidiary company has filed a petition with the Hon'ble High Court of Judicature at Hyderabad for the states Andhra Pradesh and Telangana for amalgamation with Granules India Limited with effect from 1st April 2013, the Appointed Date. Subsequent to approval of Hon'ble High Court of Judicature at Hyderabad for the States of Andhra Pradesh and Telangana, the accounts of Granules India Limited will be revised accordingly.
- Pursuant to the Notification No.G.S.R.913(E), dt.29.12.2011 issued by the Ministry of Company Affairs, the company has opted to capitalise foreign currency gains and losses on loans utilised for purchase of fixed assets. - During the quarter Gain of Rs.108.01 lakhs (Loss of Rs.1,478.51 Lakhs for the Quarter ended 30 June 2013) was transferred to fixed assets.
- As per clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company's website as well as on the stock exchanges' websites as stated below:
www.granulesindia.com, www.bseindia.com and www.nse-india.com
- The Company operates only in the segment of Pharmaceuticals.
- Figures are regrouped wherever necessary.
- The Company, during the current year has allotted 75,000 equity shares of Rs.10/- each, fully paid up, on exercise of options by employees, in accordance with the Company's Employee Stock Option Scheme(s).
- The current quarter figures are not comparable with the corresponding previous year figures as the accounts of the Auctus Pharma Limited were consolidated w.e.f., 14-02-2014.
- Standalone Results as on 30.6.2014 are as under -

Particulars	Quarter ended			31-Mar-14
	30-Jun-14	31-Mar-14	30-Jun-13	
	Un-Audited	Audited	Un-Audited	Audited
Net Sales/Income from Operations	25,344.90	29,184.44	20,871.18	1,00,167.99
Profit Before Tax	3,315.03	3,876.75	2,214.87	12,133.08
Profit After Tax	2,234.94	2,604.26	1,473.20	8,101.14

for and on behalf of the Board

Place : Hyderabad
Date : 24th July, 2014

Chairman

